SUPPLEMENT NO. 4 DATED 6 NOVEMBER 2025 TO THE BASE PROSPECTUS DATED 18 JULY 2025



Bank of America Corporation

(a Delaware (U.S.A.) Corporation)

Merrill Lynch B.V.

(a Dutch Private Limited Liability Company)

NOTE, WARRANT AND CERTIFICATE PROGRAMME

Unconditionally and irrevocably guaranteed (in respect of Instruments issued by Merrill Lynch B.V.)

by

Bank of America Corporation

Supplement to the Base Prospectus

This supplement (the "Supplement") to the base prospectus of Bank of America Corporation ("BAC") and Merrill Lynch B.V. ("MLBV") dated 18 July 2025 (the "Original Base Prospectus") (as supplemented on 12 August 2025, 14 October 2025 and 22 October, and together with this Supplement, the "Base Prospectus"), prepared in connection with the Note, Warrant and Certificate Programme (the "Programme") of BAC and MLBV constitutes a supplement for the purposes of Article 23(1) of Regulation (EU) 2017/1129 (as amended, the "EU Prospectus Regulation"). Terms defined in the Base Prospectus have the same meanings when used in this Supplement.

On 18 July 2025, the Base Prospectus was approved by the *Commission de Surveillance du Secteur Financier* (the "CSSF") as competent authority under the EU Prospectus Regulation and by the Luxembourg Stock Exchange for the purpose of giving information with regard to the issue of Exempt Instruments only by the Issuers under the Programme during the period of 12 months from the date of the Base Prospectus.

This Supplement is supplemental to, and shall be read in conjunction with, the Base Prospectus. To the extent that there is any inconsistency between (a) any statement in this Supplement or any statement incorporated by reference into the Base Prospectus by this Supplement and (b) any other statement in or incorporated by reference into the Base Prospectus, the statements in (a) above will prevail.

The Supplement has been approved by the CSSF as competent authority under the EU Prospectus Regulation. The CSSF only approves the Supplement as meeting the standards of completeness, comprehensibility and consistency imposed by the EU Prospectus Regulation. The CSSF does not approve the information relating to the issue of Exempt Instruments.

The Supplement has also been approved by the Luxembourg Stock Exchange under Part IV of the Luxembourg law dated 16 July 2019 on prospectuses for securities, for the purpose of giving information with regard to the issue of Exempt Instruments. The Supplement has been deposited with SIX Exchange Regulation Ltd. in its capacity as review body pursuant to article 54 of the Swiss Financial Services Act of 15 June 2018, as amended.

Right of withdrawal

In accordance with Article 23(2) of the EU Prospectus Regulation, investors in the European Economic Area who have already agreed to purchase or subscribe for Instruments issued under the Base Prospectus before this Supplement is published and where the Instruments have not yet been delivered to them at the time when the significant new factor, material mistake or material inaccuracy to which this Supplement relates arose or was noted have the right, exercisable within three working days after the publication of this Supplement, to withdraw their acceptances, provided that the significant new factor, material mistake or material inaccuracy to which this Supplement relates arose or was noted before the closing of the offer period or the delivery of the securities, whichever occurs first. This right is exercisable up to, and including, 11 November 2025. Investors may contact the relevant Authorised Offeror(s) (as set out in the Final Terms of the relevant Instruments) should they wish to exercise such right of withdrawal.

Responsibility

BAC accepts responsibility for the information contained in this Supplement and to the best of the knowledge of BAC, the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect its import.

MLBV accepts responsibility for the information contained in this Supplement other than the information contained in (a) the document incorporated by reference in respect of BAC, and (b) statements in respect of BAC under the section entitled "General Information" (the "MLBV Information"). MLBV confirms that the MLBV Information contained in this Supplement is, to the best of its knowledge, in accordance with the facts and does not omit anything likely to affect its import.

Purpose of this Supplement

The purpose of this Supplement is to:

- incorporate by reference BAC's quarterly report on Form 10-Q for the quarter ended 30 September 2025, filed with the United States Securities and Exchange Commission (the "SEC") on 31 October 2025;
- update the section of the Base Prospectus entitled "Product Conditions"; and
- update the section of the Base Prospectus entitled "General Information".

Application of Amendments in this Supplement

The amendments included in this supplement to terms and conditions of the Instruments and form of the final terms shall only apply to final terms, the date and time of which falls on or after the approval of this supplement.

Information being supplemented

1. Document incorporated by reference

The following document, which has previously been published and has been filed with the CSSF, shall be deemed to be incorporated in, and to form part of, the Base Prospectus:

(a) BAC's Quarterly Report on Form 10-Q for the quarter ended 30 September 2025 filed with the SEC on 31 October 2025 (available for viewing at https://dl.luxse.com/dlp/103f20fe4ef78046d5979b557ac574753e) (the "BAC 30 September 2025 Quarterly Report"),

(other than with respect to this report, information that is furnished but deemed not to have been filed under the rules of the SEC).

Document Incorporated by Reference Cross-Reference List

BAC 30 September 2025 Quarterly Report	Page Number
Part I Financial Information	_
Item 1. Financial Statements	
Consolidated Statement of Income	Page 48
Consolidated Statement of Comprehensive Income	Page 48
Consolidated Balance Sheet	Page 49
Consolidated Statement of Changes in Shareholders' Equity	Page 50
Consolidated Statement of Cash Flows	Page 51
Notes to Consolidated Financial Statements	Pages 52-103
1 – Summary of Significant Accounting Principles	Page 52
2 – Net Interest Income and Noninterest Income	Page 53
3 – Derivatives	Pages 54-60
4 – Securities	Pages 61-63
5 – Outstanding Loans and Leases and Allowance for Credit Losses	Pages 64-75
6 – Securitizations and Other Variable Interest Entities	Pages 75-79
7 – Goodwill and Intangible Assets	Page 80
8 – Leases	Page 80
9 – Securities Financing Agreements, Collateral and Restricted Cash	Pages 81-82
10 – Commitments and Contingencies	Pages 82-85
11 – Shareholders' Equity	Page 85
12 – Accumulated Other Comprehensive Income (Loss)	Page 86
13 – Earnings Per Common Share	Page 87
14 – Fair Value Measurements	Pages 87-94
15 – Fair Value Option	Pages 94-96
16 – Fair Value of Financial Instruments	Page 96
17 – Business Segment Information	Pages 97-100
Glossary	Pages 101-102
Acronyms	Page 103
Teronyma	ruge ros
Item 2. Management's Discussion and Analysis of Financial Condition and Results of	
Operations	
Executive Summary	Page 3
Recent Developments	Page 3
Financial Highlights	Pages 4-6
Supplemental Financial Data	Pages 7-10
Business Segment Operations	Page 11
Consumer Banking	Pages 11-13
Global Wealth & Investment Management	Pages 13-14
Global Banking	Pages 15-17
Global Markets	Pages 17-19
All Other	Page 19
Managing Risk	Page 20
Capital Management	Pages 20-24
Liquidity Risk	Pages 25-28
Credit Risk Management	Page 28
Consumer Portfolio Credit Risk Management	Pages 28-33
Commercial Portfolio Credit Risk Management	Pages 33-39
Non-U.S. Portfolio	Page 39
Allowance for Credit Losses	Pages 40-41

Market Risk Management	Page 42
Trading Risk Management	Pages 42-44
Interest Rate Risk Management for the Banking Book	Pages 44-46
Mortgage Banking Risk Management	Page 46
Climate Risk	Page 46
Complex Accounting Estimates	Page 46
Non-GAAP Reconciliations	Page 47
Item 3. Quantitative and Qualitative Disclosures about Market Risk	Page 47
Item 4. Controls and Procedures	Page 47
Part II Other Information	
Item 1. Legal Proceedings	Page 104
Item 1A. Risk Factors	Page 104
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	Page 104
Item 5. Other Information	Page 104
Item 6. Exhibits	Page 105
Signature	Page 105

The following table indicates where information required by the Commission Delegated Regulation (EU) 2019/980 supplementing Regulation (EU) 2017/1129 of the European Parliament and of the Council and repealing Commission (EC) No 809/2004 (as amended, the "EU PR Regulation") to be disclosed in, and incorporated by reference into, this Base Prospectus can be found in the documents referred to above.

Information about BAC

Information required by the EU PR Regulation	Document/Location
Expected Financing Activities (Annex 6, Section 4, Item 4.1.8 of the EU PR Regulation)	BAC 30 September 2025 Quarterly Report (pages 26-27, 85)
Legal and arbitration proceedings (Annex 6, Section 11, Item 11.4.1 of the EU PR Regulation)	BAC 30 September 2025 Quarterly Report (pages 84-85)
Share Capital of BAC (Annex 6, Section 12, Item 12.1 of the EU PR Regulation)	BAC 30 September 2025 Quarterly Report (page 85)

Any information included in the BAC 30 September 2025 Quarterly Report that is not included in the cross-reference list is not incorporated by reference and is therefore either (a) covered elsewhere in the Base Prospectus; or (b) not relevant to an investor (meaning that it is not necessary information to be included in the Base Prospectus pursuant to Article 6(1) of the EU Prospectus Regulation and is not otherwise required to be included under the relevant schedules of the EU PR Regulation).

2. Updating of the section entitled "Product Conditions"

The information contained within the "*Product Conditions*" section on page 635 of the Original Base Prospectus in paragraph 4.2 entitled "*Capital Repayable with Participation*", shall be deleted and replaced with the following wording:

"4.2 Capital Repayable with Participation

This Product Condition 4.2 applies if the Issue Terms specify that "Capital Repayable with Participation" is applicable.

- 4.2.1 **Barrier Event is Not Applicable**: This Product Sub-Condition 4.2.1 applies where Barrier Event is specified as not applicable in the Issue Terms, subject to and in accordance with the following subparagraph(s) (as applicable):
 - (a) **Cap is Not Applicable**: if Cap is specified as not applicable in the Issue Terms, then the Final Settlement Amount shall be calculated in accordance with the following formula:

```
NA \times \{100\% + Max[Participation \times (Final Performance - Call Strike); Floor]\}
```

(b) **Cap is Applicable**: if a Cap is specified in the Issue Terms, then the Final Settlement Amount shall be calculated in accordance with the following formula:

 $NA \times \{100\% + Max[Participation \times Min[(Final Performance - Call Strike); Cap]; Floor]\}$

- 4.2.2 **Barrier Event is Applicable**: This Product Sub-Condition 4.2.2 applies where Barrier Event is specified as applicable in the Issue Terms, subject to and in accordance with the following sub-paragraph(s) (as applicable):
 - (a) **Barrier Upper Event is Not Applicable**: if Barrier Upper Event is specified as not applicable in the Issue Terms and:
 - (i) a Barrier Event has not occurred and where:
 - (A) **Cap is Not Applicable**: if Cap is specified as not applicable in the Issue Terms, then the Final Settlement Amount shall be calculated in accordance with the following formula:

```
NA \times \{100\% + Max[Participation \times (Final Performance - Call Strike); Floor]\}
```

(B) **Cap is Applicable**: if a Cap is specified in the Issue Terms, then the Final Settlement Amount shall be calculated in accordance with the following formula:

 $NA \times \{100\% + Max[Participation x Min[(Final Performance - Call Strike); Cap]; Floor]\}$

- (ii) a Barrier Event has occurred and where:
 - (A) **Rebate is Not Applicable**: if Rebate is specified as not applicable in the Issue Terms, then the Final Settlement Amount shall be calculated in accordance with the following formula:

$$NA \times 100\%$$

(B) **Rebate is Applicable**: if a Rebate is specified in the Issue Terms, then the Final Settlement Amount shall be calculated in accordance with the following formula:

$$NA \times (100\% + Rebate)$$

- (b) **Barrier Upper Event is Applicable:** if Barrier Upper Event is specified as applicable in the Issue Terms and:
 - (i) if a Barrier Event has not occurred and:
 - (A) if a Barrier Upper Event has occurred and:
 - (1) **Cap is Not Applicable**: if Cap is specified as not applicable in the Issue Terms, the Final Settlement Amount shall be calculated in accordance with the following formula:

NA \times {100% + Max[Participation Up \times (Final Performance – Call Strike); Floor]}

(2) **Cap is Applicable**: if a Cap is specified in the Issue Terms, the Final Settlement Amount shall be calculated in accordance with the following formula:

 $NA \times \{100\% + Max[Participation Up \times Min[(Final Performance - Call Strike); Cap]; Floor]\}$

- (B) If a Barrier Upper Event has not occurred and:
 - (1) Cap is Not Applicable: if Cap is specified as not applicable in the Issue Terms, the Final Settlement Amount shall be calculated in accordance with the following formula:

 $NA \times \{100\% + Max[Participation Down \times (Put Strike - Final Performance); Floor]\}$

(2) **Cap is Applicable**: if a Cap is specified in the Issue Terms, the Final Settlement Amount shall be calculated in accordance with the following formula:

 $NA \times \{100\% + Max[Participation Down x Min[(Put Strike - Final Performance); Cap]; Floor]\}$

- (ii) if a Barrier Event has occurred and:
 - (A) **Rebate is Not Applicable**: if Rebate is specified as not applicable in the Issue Terms, the Final Settlement Amount shall be calculated in accordance with the following formula:

$$NA \times 100\%$$

(B) **Rebate is Applicable**: if a Rebate is specified in the Issue Terms, the Final Settlement Amount shall be calculated in accordance with the following formula:

$$NA \times (100\% + Rebate)$$
"

- 3. Updating of the section entitled "General Information"
 - (a) The information contained within the "*General Information*" section on page 762 of the Original Base Prospectus at paragraph (6) entitled "*Significant or Material Change*", shall be deleted and replaced with the following information:

"The following statements are made solely in the context of the issuance of Instruments under this Base Prospectus. Material information about the respective financial condition and prospects of each Issuer and the Guarantor is included in each of the relevant Issuer's and Guarantor's annual and interim reports, as applicable, which are incorporated by reference into this Base Prospectus.

There has been no significant change in the financial position or financial performance of BAC and its subsidiaries on a consolidated basis since 30 September 2025. There has been no significant change in the financial position or financial performance of MLBV since 30 June 2025.

There has been no material adverse change in the prospects of MLBV or BAC and its subsidiaries on a consolidated basis since 31 December 2024."

(b) The information contained within the "*General Information*" section on page 762 of the Original Base Prospectus at paragraph (7) entitled "*Litigation*", shall be deleted and replaced with the following information:

"Save as disclosed in (i) the section entitled "Litigation and Regulatory Matters" on pages 138 to 139, being the Litigation and Regulatory Matters section in Note 12 to the Consolidated Financial Statements, of the BAC 2024 Annual Report and (ii) the section entitled "Litigation and Regulatory Matters" on pages 84 to 85, being the Litigation and Regulatory Matters section in Note 10 to the Consolidated

Financial Statements, of the BAC 30 September 2025 Quarterly Report, none of MLBV, BAC and any subsidiary of BAC is or has been involved in any governmental, legal or arbitration proceedings (including any such proceedings which are pending or threatened of which MLBV or BAC are aware) in the 12 months preceding the date of this Base Prospectus which may have or have in such period had a significant effect on the financial position or profitability of MLBV or BAC and its subsidiaries on a consolidated basis."

General

This Supplement and the document incorporated by reference will be available for viewing and can be obtained during normal business hours from the specified office of the applicable Paying Agent (in respect of Notes) and the applicable W&C Instrument Agent (in respect of W&C Instruments) and on the Luxembourg Stock Exchange's website at www.luxse.com.